Insufficient scRNA-seq data for expression of IL17A at single-cell level.
Insufficient scRNA-seq data for expression of IL17A at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 25% | 2.52 | 244 / 966 | 20% | 0.53 | 103 / 527 |
lung | 32% | 3.23 | 184 / 578 | 4% | 0.09 | 43 / 1155 |
stomach | 17% | 1.52 | 60 / 359 | 17% | 0.56 | 50 / 286 |
esophagus | 16% | 3.04 | 237 / 1445 | 11% | 0.34 | 20 / 183 |
peripheral blood | 27% | 1.43 | 249 / 929 | 0% | 0 | 0 / 0 |
bladder | 14% | 0.71 | 3 / 21 | 9% | 0.20 | 43 / 504 |
tonsil | 0% | 0 | 0 / 0 | 16% | 0.31 | 7 / 45 |
spleen | 14% | 1.08 | 33 / 241 | 0% | 0 | 0 / 0 |
prostate | 11% | 0.74 | 27 / 245 | 1% | 0.03 | 4 / 502 |
kidney | 11% | 0.31 | 10 / 89 | 0% | 0 | 0 / 901 |
uterus | 5% | 0.21 | 8 / 170 | 5% | 0.11 | 24 / 459 |
liver | 8% | 0.27 | 17 / 226 | 0% | 0.01 | 2 / 406 |
lymph node | 0% | 0 | 0 / 0 | 7% | 1.42 | 2 / 29 |
thymus | 6% | 0.14 | 36 / 653 | 0% | 0 | 0 / 605 |
adipose | 5% | 0.41 | 60 / 1204 | 0% | 0 | 0 / 0 |
muscle | 4% | 0.16 | 35 / 803 | 0% | 0 | 0 / 0 |
skin | 3% | 0.22 | 52 / 1809 | 1% | 0.01 | 3 / 472 |
breast | 3% | 0.39 | 13 / 459 | 0% | 0.00 | 2 / 1118 |
adrenal gland | 3% | 0.05 | 7 / 258 | 0% | 0 | 0 / 230 |
pancreas | 2% | 0.05 | 7 / 328 | 1% | 0.01 | 1 / 178 |
blood vessel | 2% | 0.06 | 31 / 1335 | 0% | 0 | 0 / 0 |
ovary | 2% | 0.06 | 4 / 180 | 0% | 0 | 0 / 430 |
brain | 2% | 0.06 | 49 / 2642 | 0% | 0 | 0 / 705 |
heart | 2% | 0.03 | 13 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030216 | Biological process | keratinocyte differentiation |
GO_0050832 | Biological process | defense response to fungus |
GO_0097530 | Biological process | granulocyte migration |
GO_0072537 | Biological process | fibroblast activation |
GO_0006954 | Biological process | inflammatory response |
GO_0032755 | Biological process | positive regulation of interleukin-6 production |
GO_0007219 | Biological process | Notch signaling pathway |
GO_2000340 | Biological process | positive regulation of chemokine (C-X-C motif) ligand 1 production |
GO_0038173 | Biological process | interleukin-17A-mediated signaling pathway |
GO_0008219 | Biological process | cell death |
GO_0045087 | Biological process | innate immune response |
GO_0032747 | Biological process | positive regulation of interleukin-23 production |
GO_0050829 | Biological process | defense response to Gram-negative bacterium |
GO_0032735 | Biological process | positive regulation of interleukin-12 production |
GO_0002225 | Biological process | positive regulation of antimicrobial peptide production |
GO_0071347 | Biological process | cellular response to interleukin-1 |
GO_1903348 | Biological process | positive regulation of bicellular tight junction assembly |
GO_0007267 | Biological process | cell-cell signaling |
GO_1900017 | Biological process | positive regulation of cytokine production involved in inflammatory response |
GO_0045672 | Biological process | positive regulation of osteoclast differentiation |
GO_0032731 | Biological process | positive regulation of interleukin-1 beta production |
GO_0006955 | Biological process | immune response |
GO_0002250 | Biological process | adaptive immune response |
GO_0050830 | Biological process | defense response to Gram-positive bacterium |
GO_0006915 | Biological process | apoptotic process |
GO_0010467 | Biological process | gene expression |
GO_0106015 | Biological process | negative regulation of inflammatory response to wounding |
GO_0060729 | Biological process | intestinal epithelial structure maintenance |
GO_0032739 | Biological process | positive regulation of interleukin-16 production |
GO_0009611 | Biological process | response to wounding |
GO_0032760 | Biological process | positive regulation of tumor necrosis factor production |
GO_0043616 | Biological process | keratinocyte proliferation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0097400 | Biological process | interleukin-17-mediated signaling pathway |
GO_0005615 | Cellular component | extracellular space |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005576 | Cellular component | extracellular region |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0046982 | Molecular function | protein heterodimerization activity |
GO_0005515 | Molecular function | protein binding |
GO_0005125 | Molecular function | cytokine activity |
Gene name | IL17A |
Protein name | Interleukin 17A Interleukin-17A (IL-17) (IL-17A) (Cytotoxic T-lymphocyte-associated antigen 8) (CTLA-8) |
Synonyms | CTLA8 IL17 |
Description | FUNCTION: Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity . Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation . Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites (By similarity). In airway epithelium, mediates neutrophil chemotaxis via induction of CXCL1 and CXCL5 chemokines (By similarity). In secondary lymphoid organs, contributes to germinal center formation by regulating the chemotactic response of B cells to CXCL12 and CXCL13, enhancing retention of B cells within the germinal centers, B cell somatic hypermutation rate and selection toward plasma cells (By similarity). Effector cytokine of a subset of gamma-delta T cells that functions as part of an inflammatory circuit downstream IL1B, TLR2 and IL23A-IL12B to promote neutrophil recruitment for efficient bacterial clearance (By similarity). Effector cytokine of innate immune cells including invariant natural killer cell (iNKT) and group 3 innate lymphoid cells that mediate initial neutrophilic inflammation (By similarity). Involved in the maintenance of the integrity of epithelial barriers during homeostasis and pathogen infection . Upon acute injury, has a direct role in epithelial barrier formation by regulating OCLN localization and tight junction biogenesis (By similarity). As part of the mucosal immune response induced by commensal bacteria, enhances host's ability to resist pathogenic bacterial and fungal infections by promoting neutrophil recruitment and antimicrobial peptides release (By similarity). In synergy with IL17F, mediates the production of antimicrobial beta-defensins DEFB1, DEFB103A, and DEFB104A by mucosal epithelial cells, limiting the entry of microbes through the epithelial barriers (By similarity). Involved in antiviral host defense through various mechanisms (By similarity). Enhances immunity against West Nile virus by promoting T cell cytotoxicity (By similarity). May play a beneficial role in influenza A virus (H5N1) infection by enhancing B cell recruitment and immune response in the lung (By similarity). Contributes to influenza A virus (H1N1) clearance by driving the differentiation of B-1a B cells, providing for production of virus-specific IgM antibodies at first line of host defense (By similarity). . |
Accessions | Q16552 Q6NZ94 ENST00000648244.1 |